IRIS Accounts Production v25.4.0.155 13182416 director 1.3.24 28.2.25 28.2.25 false true false false true false Ordinary Share 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 13182416 2024-02-29 13182416 2025-02-28 13182416 2024-03-01 2025-02-28 13182416 2023-02-28 13182416 2023-03-01 2024-02-29 13182416 2024-02-29 13182416 ns15:EnglandWales 2024-03-01 2025-02-28 13182416 ns14:PoundSterling 2024-03-01 2025-02-28 13182416 ns10:Director1 2024-03-01 2025-02-28 13182416 ns10:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 13182416 ns10:SmallEntities 2024-03-01 2025-02-28 13182416 ns10:AuditExempt-NoAccountantsReport 2024-03-01 2025-02-28 13182416 ns10:SmallCompaniesRegimeForDirectorsReport 2024-03-01 2025-02-28 13182416 ns10:SmallCompaniesRegimeForAccounts 2024-03-01 2025-02-28 13182416 ns10:FullAccounts 2024-03-01 2025-02-28 13182416 ns10:OrdinaryShareClass1 2024-03-01 2025-02-28 13182416 ns10:RegisteredOffice 2024-03-01 2025-02-28 13182416 ns5:CurrentFinancialInstruments 2025-02-28 13182416 ns5:CurrentFinancialInstruments 2024-02-29 13182416 ns5:Non-currentFinancialInstruments 2025-02-28 13182416 ns5:Non-currentFinancialInstruments 2024-02-29 13182416 ns5:ShareCapital 2025-02-28 13182416 ns5:ShareCapital 2024-02-29 13182416 ns5:RetainedEarningsAccumulatedLosses 2025-02-28 13182416 ns5:RetainedEarningsAccumulatedLosses 2024-02-29 13182416 ns5:PlantMachinery 2024-02-29 13182416 ns5:PlantMachinery 2024-03-01 2025-02-28 13182416 ns5:PlantMachinery 2025-02-28 13182416 ns5:PlantMachinery 2024-02-29 13182416 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-02-28 13182416 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-02-29 13182416 ns10:OrdinaryShareClass1 2025-02-28

REGISTERED NUMBER: 13182416 (England and Wales)

| Unaudited Financial Statements |

| for the Year Ended 28 February 2025 |

| for |

| Icardiology UK Ltd |

| Icardiology UK Ltd (Registered number: 13182416) |

Contents of the Financial Statements

for the Year Ended 28 February 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 4 |

| Icardiology UK Ltd |

Company Information

for the Year Ended 28 February 2025

| DIRECTOR: | Shakeel Osman

| REGISTERED OFFICE: | Justa House

| 204-208 Holbrook Lane

| Coventry

| England

| CV6 4DD

| REGISTERED NUMBER: | 13182416 (England and Wales)

| ACCOUNTANTS: | SKS Justa & Co Ltd

| Justa House

| 206-208 Holbrook Lane

| Coventry

| CV6 4DD

| Icardiology UK Ltd (Registered number: 13182416) |

Balance Sheet

28 February 2025

| 2025 |  | 2024

| Notes | £ | £ |

Fixed assets

Tangible assets | 4 | 3,776 |  | 4,442 |  |

Current assets

Stocks | 11,635 |  | 5,790 |  |

Debtors | 5 | 1,252,106 |  | 725,853 |  |

Cash at bank and in hand | 12,151 |  | 14,575 |  |

1,275,892 |  | 746,218 |  |

Creditors

Amounts falling due within one year | 6 | (928,946 | ) | (565,454 | ) |

Net current assets | 346,946 |  | 180,764 |  |

Total assets less current liabilities | 350,722 |  | 185,206 |  |

Creditors

Amounts falling due after more than one year | 7 | (14,500 | ) | (69,998 | ) |

Net assets | 336,222 |  | 115,208 |  |

Capital and reserves

Called up share capital | 8 | 500 |  | 500 |  |

Retained earnings | 335,722 |  | 114,708 |  |

Shareholders' funds | 336,222 |  | 115,208 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 28 February 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 28 February 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

| Icardiology UK Ltd (Registered number: 13182416) |

Balance Sheet - continued

28 February 2025

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 20 January 2026 and were signed by:

Shakeel Osman - Director

| Icardiology UK Ltd (Registered number: 13182416) |

Notes to the Financial Statements

for the Year Ended 28 February 2025

1. | STATUTORY INFORMATION

| Icardiology UK Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | ACCOUNTING POLICIES

| BASIS OF PREPARING THE FINANCIAL STATEMENTS

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| TURNOVER

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes for the goods sold in the normal course of business.

| TANGIBLE FIXED ASSETS

| Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

| Depreciation is recognised so as to write off the cost or valuation of assets less residual values over the useful life on the following basis:

| Fixtures and fittings 15% WDV

| The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

| TAXATION

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| CASH AND CASH EQUIVALENTS

| Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

| Icardiology UK Ltd (Registered number: 13182416) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2025

2. | ACCOUNTING POLICIES - continued

| FINANCIAL INSTRUMENTS

| The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

| Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

| Financial assets and liabilities are offset, with the net amounts presented in the financial statements ,when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

| BASIC FINANCIAL ASSETS

| Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

| CLASSIFICATION OF FINANCIAL LIABILITIES

| Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

| BASIC FINANCIAL LIABILITIES

| Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

| Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

| Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

| EQUITY INSTRUMENTS

| Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

| EMPLOYEE BENEFIT

| The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

| The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

| Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 4 (2024 - 4 ) .

| Icardiology UK Ltd (Registered number: 13182416) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2025

4. | TANGIBLE FIXED ASSETS

| Plant and

| machinery

| etc

£ |

| COST

| At 1 March 2024

| and 28 February 2025 | 6,888 |  |

| DEPRECIATION

| At 1 March 2024 | 2,446 |  |

| Charge for year | 666 |  |

| At 28 February 2025 | 3,112 |  |

| NET BOOK VALUE

| At 28 February 2025 | 3,776 |  |

| At 29 February 2024 | 4,442 |  |

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 174,677 |  | 113,279 |  |

| Other debtors | 1,077,429 |  | 612,574 |  |

1,252,106 |  | 725,853 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade creditors | 326,159 |  | 343,885 |  |

| Taxation and social security | 249,992 |  | 132,699 |  |

| Other creditors | 352,795 |  | 88,870 |  |

928,946 |  | 565,454 |  |

7. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

2025 | 2024 |

£ | £ |

| Bank loans | 14,500 |  | 69,998 |  |

| Icardiology UK Ltd (Registered number: 13182416) |

Notes to the Financial Statements - continued

for the Year Ended 28 February 2025

7. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR - continued

2025 | 2024 |

£ | £ |

| Amounts falling due in more than five years:

| Repayable by instalments

| Loan from BMT Medical | - |  | 19,998 |  |

| Loan from Anthony Gillbert | 14,500 |  | 50,000 |  |

14,500 |  | 69,998 |  |

8. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 500 | Ordinary Share | 1 | 500 |  | 500 |  |